{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T13:08:23Z","timestamp":1776172103679,"version":"3.50.1"},"reference-count":76,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100014810","name":"Sardegna Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014810","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021856","name":"Ministero dell'Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021856","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Neurology"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.expneurol.2024.115040","type":"journal-article","created":{"date-parts":[[2024,11,3]],"date-time":"2024-11-03T15:00:39Z","timestamp":1730646039000},"page":"115040","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Early \u03b1-synuclein\/synapsin III co-accumulation, nigrostriatal dopaminergic synaptopathy and denervation in the MPTPp mouse model of Parkinson's Disease"],"prefix":"10.1016","volume":"383","author":[{"given":"Marcello","family":"Serra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaia","family":"Faustini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viviana","family":"Brembati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Antonietta","family":"Casu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Pizzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Micaela","family":"Morelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annalisa","family":"Pinna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arianna","family":"Bellucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.expneurol.2024.115040_bb0005","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.parkreldis.2018.02.046","article-title":"Neurite orientation dispersion and density imaging of the nigrostriatal pathway in Parkinson\u2019s disease: retrograde degeneration observed by tract-profile analysis","volume":"51","author":"Andica","year":"2018","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.expneurol.2024.115040_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2023.107715","article-title":"Active shrinkage protects neurons following axonal transection","volume":"26","author":"Aydin","year":"2023","journal-title":"iScience"},{"key":"10.1016\/j.expneurol.2024.115040_bb0015","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13024-015-0067-y","article-title":"Novel (hetero)arylalkenyl propargylamine compounds are protective in toxin-induced models of Parkinson\u2019s disease","volume":"11","author":"Baranyi","year":"2016","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.expneurol.2024.115040_bb0020","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1111\/j.1471-4159.2008.05406.x","article-title":"Alpha-synuclein aggregation and cell death triggered by energy deprivation and dopamine overload are counteracted by D2\/D3 receptor activation","volume":"106","author":"Bellucci","year":"2008","journal-title":"J. Neurochem."},{"key":"10.1016\/j.expneurol.2024.115040_bb0025","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0027959","article-title":"Redistribution of DAT\/alpha-synuclein complexes visualized by \"in situ\" proximity ligation assay in transgenic mice modelling early Parkinson's disease","volume":"6","author":"Bellucci","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.expneurol.2024.115040_bb0030","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.brainres.2011.11.031","article-title":"Alpha-Synuclein synaptic pathology and its implications in the development of novel therapeutic approaches to cure Parkinson\u2019s disease","volume":"1432","author":"Bellucci","year":"2012","journal-title":"Brain Res."},{"key":"10.1016\/j.expneurol.2024.115040_bb0035","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/nan.12297","article-title":"Review: Parkinson\u2019s disease: from synaptic loss to connectome dysfunction","volume":"42","author":"Bellucci","year":"2016","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"10.1016\/j.expneurol.2024.115040_bb0040","doi-asserted-by":"crossref","first-page":"330","DOI":"10.3389\/fnagi.2017.00330","article-title":"The end is the beginning: Parkinson\u2019s disease in the light of brain imaging","volume":"9","author":"Bellucci","year":"2017","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.expneurol.2024.115040_bb0045","unstructured":"Bellucci, A. C.; Longhena, F.; Straniero, V.; Valoti, E. , 2021. Structural analogues of methylphenidate as Parkinson's disease-modifying agents. Patent WO2022\/029151 A1."},{"key":"10.1016\/j.expneurol.2024.115040_bb0050","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1002\/mds.26431","article-title":"MDS research criteria for prodromal Parkinson\u2019s disease","volume":"30","author":"Berg","year":"2015","journal-title":"Mov. Disord."},{"key":"10.1016\/j.expneurol.2024.115040_bb0055","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1111\/j.1742-4658.2012.08491.x","article-title":"Animal models of Parkinson\u2019s disease","volume":"279","author":"Blandini","year":"2012","journal-title":"FEBS J."},{"key":"10.1016\/j.expneurol.2024.115040_bb0060","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.expneurol.2017.10.002","article-title":"Compensatory mechanisms in Parkinson\u2019s disease: circuits adaptations and role in disease modification","volume":"298","author":"Blesa","year":"2017","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.expneurol.2024.115040_bb0065","doi-asserted-by":"crossref","first-page":"12845","DOI":"10.1523\/JNEUROSCI.1391-15.2015","article-title":"Brain region-specific trafficking of the dopamine transporter","volume":"35","author":"Block","year":"2015","journal-title":"J. Neurosci."},{"key":"10.1016\/j.expneurol.2024.115040_bb0070","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1016\/S0140-6736(21)00218-X","article-title":"Parkinson\u2019s disease","volume":"397","author":"Bloem","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.expneurol.2024.115040_bb0075","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.neuroscience.2011.10.057","article-title":"Neurotoxin-based models of Parkinson's disease","volume":"211","author":"Bove","year":"2012","journal-title":"Neuroscience"},{"key":"10.1016\/j.expneurol.2024.115040_bb0080","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/s12640-012-9342-7","article-title":"Modulating microglia activity with PPAR-gamma agonists: a promising therapy for Parkinson\u2019s disease?","volume":"23","author":"Carta","year":"2013","journal-title":"Neurotox. Res."},{"key":"10.1016\/j.expneurol.2024.115040_bb0085","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14081595","article-title":"Methylphenidate analogues as a new class of potential disease-modifying agents for Parkinson\u2019s disease: evidence from cell models and alpha-Synuclein transgenic mice","volume":"14","author":"Casiraghi","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.expneurol.2024.115040_bb0090","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s00213-003-1663-z","article-title":"Immunocytochemical study of the forebrain serotonergic innervation in Sardinian alcohol-preferring rats","volume":"172","author":"Casu","year":"2004","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.expneurol.2024.115040_bb0095","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1097\/NEN.0000000000000064","article-title":"Neuroprotective potential of adenosine A2A and cannabinoid CB1 receptor antagonists in an animal model of Parkinson disease","volume":"73","author":"Cerri","year":"2014","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.expneurol.2024.115040_bb0100","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S1474-4422(09)70068-7","article-title":"Non-motor symptoms of Parkinson\u2019s disease: dopaminergic pathophysiology and treatment","volume":"8","author":"Chaudhuri","year":"2009","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.expneurol.2024.115040_bb0105","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s13311-012-0104-2","article-title":"A progressive mouse model of Parkinson\u2019s disease: the Thy1-aSyn (\u201cline 61\u201d) mice","volume":"9","author":"Chesselet","year":"2012","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.expneurol.2024.115040_bb0110","doi-asserted-by":"crossref","first-page":"3565","DOI":"10.1093\/brain\/awz296","article-title":"Intrastriatal alpha-synuclein fibrils in monkeys: spreading, imaging and neuropathological changes","volume":"142","author":"Chu","year":"2019","journal-title":"Brain"},{"key":"10.1016\/j.expneurol.2024.115040_bb0115","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3389\/fnagi.2018.00163","article-title":"Rhes counteracts dopamine neuron degeneration and Neuroinflammation depending on gender and age","volume":"10","author":"Costa","year":"2018","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.expneurol.2024.115040_bb0120","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S0896-6273(03)00568-3","article-title":"Parkinson's disease: mechanisms and models","volume":"39","author":"Dauer","year":"2003","journal-title":"Neuron"},{"key":"10.1016\/j.expneurol.2024.115040_bb0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1749-6632.2003.tb07458.x","article-title":"Description of Parkinson\u2019s disease as a clinical syndrome","volume":"991","author":"Fahn","year":"2003","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.expneurol.2024.115040_bb0130","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s00401-018-1892-1","article-title":"Synapsin III deficiency hampers alpha-synuclein aggregation, striatal synaptic damage and nigral cell loss in an AAV-based mouse model of Parkinson's disease","volume":"136","author":"Faustini","year":"2018","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.expneurol.2024.115040_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2020.104789","article-title":"Alpha-synuclein\/synapsin III pathological interplay boosts the motor response to methylphenidate","volume":"138","author":"Faustini","year":"2020","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.expneurol.2024.115040_bb0140","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/j.ymthe.2022.01.021","article-title":"Synapsin III gene silencing redeems alpha-synuclein transgenic mice from Parkinson\u2019s disease-like phenotype","volume":"30","author":"Faustini","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.expneurol.2024.115040_bb0145","doi-asserted-by":"crossref","first-page":"9434","DOI":"10.1523\/JNEUROSCI.3080-04.2004","article-title":"Early and progressive sensorimotor anomalies in mice overexpressing wild-type human alpha-synuclein","volume":"24","author":"Fleming","year":"2004","journal-title":"J. Neurosci."},{"key":"10.1016\/j.expneurol.2024.115040_bb0150","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.expneurol.2013.03.002","article-title":"Performance of movement in hemiparkinsonian rats influences the modifications induced by dopamine agonists in striatal efferent dynorphinergic neurons","volume":"247","author":"Frau","year":"2013","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.expneurol.2024.115040_bb0155","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s40478-023-01711-w","article-title":"Regional differences in synaptic degeneration are linked to alpha-synuclein burden and axonal damage in Parkinson\u2019s disease and dementia with Lewy bodies","volume":"12","author":"Frigerio","year":"2024","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.expneurol.2024.115040_bb0160","article-title":"A comprehensive phenotype of non-motor impairments and distribution of alpha-Synuclein deposition in parkinsonism-induced mice by a combination injection of MPTP and probenecid","volume":"12","author":"Han","year":"2020","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.expneurol.2024.115040_bb0165","doi-asserted-by":"crossref","first-page":"28849","DOI":"10.1074\/jbc.274.41.28849","article-title":"Role of cytochrome c as a stimulator of alpha-synuclein aggregation in Lewy body disease","volume":"274","author":"Hashimoto","year":"1999","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.expneurol.2024.115040_bb0170","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1002\/mds.29177","article-title":"Brain metabolic correlates of dopaminergic denervation in prodromal and early Parkinson\u2019s disease","volume":"37","author":"Kim","year":"2022","journal-title":"Mov. Disord."},{"key":"10.1016\/j.expneurol.2024.115040_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110576","article-title":"Papaverine inhibits alpha-synuclein aggregation by modulating neuroinflammation and matrix metalloproteinase-3 expression in the subacute MPTP\/P mouse model of Parkinson\u2019s disease","volume":"130","author":"Leem","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.expneurol.2024.115040_bb0180","doi-asserted-by":"crossref","first-page":"5012129","DOI":"10.1155\/2017\/5012129","article-title":"The contribution of alpha-Synuclein spreading to Parkinson\u2019s disease Synaptopathy","volume":"2017","author":"Longhena","year":"2017","journal-title":"Neural Plast."},{"key":"10.1016\/j.expneurol.2024.115040_bb0185","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1111\/bpa.12587","article-title":"Synapsin III is a key component of alpha-synuclein fibrils in Lewy bodies of PD brains","volume":"28","author":"Longhena","year":"2018","journal-title":"Brain Pathol."},{"key":"10.1016\/j.expneurol.2024.115040_bb0190","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41531-023-00586-x","article-title":"Dopaminergic denervation and associated MRI microstructural changes in the nigrostriatal projection in early Parkinson's disease patients","volume":"9","author":"Lopez-Aguirre","year":"2023","journal-title":"NPJ Parkinsons Dis."},{"key":"10.1016\/j.expneurol.2024.115040_bb0195","doi-asserted-by":"crossref","DOI":"10.21769\/BioProtoc.3337","article-title":"Cylinder test to assess sensory-motor function in a mouse model of Parkinson\u2019s disease","volume":"9","author":"Magno","year":"2019","journal-title":"Bio-Protoc."},{"key":"10.1016\/j.expneurol.2024.115040_bb0200","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2022.810860","article-title":"The disease modification conundrum in Parkinson\u2019s disease: failures and hopes","volume":"14","author":"Mari","year":"2022","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.expneurol.2024.115040_bb0205","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1002\/mds.21010","article-title":"Behavioral models of Parkinson\u2019s disease in rodents: a new look at an old problem","volume":"21","author":"Meredith","year":"2006","journal-title":"Mov. Disord."},{"key":"10.1016\/j.expneurol.2024.115040_bb0210","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3233\/JPD-2011-11023","article-title":"MPTP mouse models of Parkinson\u2019s disease: an update","volume":"1","author":"Meredith","year":"2011","journal-title":"J. Parkinsons Dis."},{"issue":"Suppl. 2","key":"10.1016\/j.expneurol.2024.115040_bb0215","doi-asserted-by":"crossref","first-page":"S112","DOI":"10.1016\/j.parkreldis.2008.04.012","article-title":"Modeling PD pathogenesis in mice: advantages of a chronic MPTP protocol","volume":"14","author":"Meredith","year":"2008","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.expneurol.2024.115040_bb0220","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0140-6736(23)01478-2","article-title":"The pathogenesis of Parkinson\u2019s disease","volume":"403","author":"Morris","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.expneurol.2024.115040_bb0225","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/(SICI)1098-2396(199706)26:2<194::AID-SYN10>3.0.CO;2-Y","article-title":"Vesicular monoamine transporter-2: immunogold localization in striatal axons and terminals","volume":"26","author":"Nirenberg","year":"1997","journal-title":"Synapse"},{"key":"10.1016\/j.expneurol.2024.115040_bb0230","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/S1054-3589(08)60737-1","article-title":"Ultrastructural localization of the vesicular monoamine transporter 2 in mesolimbic and nigrostriatal dopaminergic neurons","volume":"42","author":"Nirenberg","year":"1998","journal-title":"Adv. Pharmacol."},{"key":"10.1016\/j.expneurol.2024.115040_bb0235","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1001\/jamaneurol.2017.3202","article-title":"Observations on a 2-step approach to screening for Parkinson disease","volume":"74","author":"Noyce","year":"2017","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.expneurol.2024.115040_bb0240","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1002\/mds.27115","article-title":"Past, present, and future of Parkinson\u2019s disease: a special essay on the 200th anniversary of the shaking palsy","volume":"32","author":"Obeso","year":"2017","journal-title":"Mov. Disord."},{"key":"10.1016\/j.expneurol.2024.115040_bb0245","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s40035-019-0165-9","article-title":"The interplay of aging, genetics and environmental factors in the pathogenesis of Parkinson\u2019s disease","volume":"8","author":"Pang","year":"2019","journal-title":"Transl Neurodegener."},{"key":"10.1016\/j.expneurol.2024.115040_bb0250","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.935784","article-title":"Characterization of Nasco grape pomace-loaded nutriosomes and their neuroprotective effects in the MPTP mouse model of Parkinson\u2019s disease","volume":"13","author":"Parekh","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.expneurol.2024.115040_bb0255","series-title":"The Mouse Brain In Stereotaxic Coordinates","author":"Paxinos","year":"2012"},{"key":"10.1016\/j.expneurol.2024.115040_bb0260","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1523\/JNEUROSCI.22-08-03090.2002","article-title":"A role for alpha-synuclein in the regulation of dopamine biosynthesis","volume":"22","author":"Perez","year":"2002","journal-title":"J. Neurosci."},{"key":"10.1016\/j.expneurol.2024.115040_bb0265","first-page":"285","article-title":"Diagnostic utility of [11C]DTBZ positron emission tomography in clinically uncertain parkinsonism: experience of a single tertiary center","volume":"70","author":"Perez-Lohman","year":"2018","journal-title":"Rev. Investig. Clin."},{"key":"10.1016\/j.expneurol.2024.115040_bb0270","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S0306-4522(01)00295-0","article-title":"Mouse model of parkinsonism: a comparison between subacute MPTP and chronic MPTP\/probenecid treatment","volume":"106","author":"Petroske","year":"2001","journal-title":"Neuroscience"},{"key":"10.1016\/j.expneurol.2024.115040_bb0275","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1002\/mds.26489","article-title":"The small GTP-binding protein Rhes influences nigrostriatal-dependent motor behavior during aging","volume":"31","author":"Pinna","year":"2016","journal-title":"Mov. Disord."},{"key":"10.1016\/j.expneurol.2024.115040_bb0280","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.neuropharm.2014.10.018","article-title":"Impairment of acquisition of intravenous cocaine self-administration by RNA-interference of dopamine D1-receptors in the nucleus accumbens shell","volume":"89","author":"Pisanu","year":"2015","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.expneurol.2024.115040_bb0285","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1749-6632.2003.tb07476.x","article-title":"The 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model: a tool to explore the pathogenesis of Parkinson\u2019s disease","volume":"991","author":"Przedborski","year":"2003","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.expneurol.2024.115040_bb0290","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1046\/j.1471-4159.2001.00183.x","article-title":"The parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a technical review of its utility and safety","volume":"76","author":"Przedborski","year":"2001","journal-title":"J. Neurochem."},{"key":"10.1016\/j.expneurol.2024.115040_bb0295","doi-asserted-by":"crossref","unstructured":"Sanchez-Catasus, C. A., et al., 2021. Dopaminergic Nigrostriatal Connectivity in Early Parkinson Disease: In Vivo Neuroimaging Study of (11)C-DTBZ PET Combined with Correlational Tractography. J. Nucl. Med. 62, 545\u2013552.","DOI":"10.2967\/jnumed.120.248500"},{"key":"10.1016\/j.expneurol.2024.115040_bb0300","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0028-3908(00)00005-8","article-title":"CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury","volume":"39","author":"Schallert","year":"2000","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.expneurol.2024.115040_bb0305","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1002\/mds.23732","article-title":"Etiology and pathogenesis of Parkinson\u2019s disease","volume":"26","author":"Schapira","year":"2011","journal-title":"Mov. Disord."},{"key":"10.1016\/j.expneurol.2024.115040_bb0310","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/mds.26620","article-title":"Early synaptic dysfunction in Parkinson\u2019s disease: insights from animal models","volume":"31","author":"Schirinzi","year":"2016","journal-title":"Mov. Disord."},{"key":"10.1016\/j.expneurol.2024.115040_bb0315","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nmeth.2089","article-title":"NIH image to ImageJ: 25 years of image analysis","volume":"9","author":"Schneider","year":"2012","journal-title":"Nat. Methods"},{"key":"10.1016\/j.expneurol.2024.115040_bb0320","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s00401-010-0711-0","article-title":"The synaptic pathology of alpha-synuclein aggregation in dementia with Lewy bodies, Parkinson\u2019s disease and Parkinson\u2019s disease dementia","volume":"120","author":"Schulz-Schaeffer","year":"2010","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.expneurol.2024.115040_bb0325","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1111\/j.1471-4159.2012.07837.x","article-title":"Aging of the dopaminergic system and motor behavior in mice intoxicated with the parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","volume":"122","author":"Schumm","year":"2012","journal-title":"J. Neurochem."},{"key":"10.1016\/j.expneurol.2024.115040_bb0330","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1038\/s41401-019-0280-2","article-title":"TLR4 deficiency has a protective effect in the MPTP\/probenecid mouse model of Parkinson\u2019s disease","volume":"40","author":"Shao","year":"2019","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.expneurol.2024.115040_bb0335","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s00441-017-2706-9","article-title":"Neurodegeneration and the ordered assembly of alpha-synuclein","volume":"373","author":"Spillantini","year":"2018","journal-title":"Cell Tissue Res."},{"key":"10.1016\/j.expneurol.2024.115040_bb0340","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/42166","article-title":"Alpha-synuclein in Lewy bodies","volume":"388","author":"Spillantini","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.expneurol.2024.115040_bb0345","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/s42003-023-04884-1","article-title":"Alpha-Synuclein fibril and synaptic vesicle interactions lead to vesicle destruction and increased lipid-associated fibril uptake into iPSC-derived neurons","volume":"6","author":"Stephens","year":"2023","journal-title":"Commun Biol."},{"key":"10.1016\/j.expneurol.2024.115040_bb0350","doi-asserted-by":"crossref","first-page":"15194","DOI":"10.1074\/jbc.M113.457408","article-title":"Lewy body-like alpha-synuclein aggregates resist degradation and impair macroautophagy","volume":"288","author":"Tanik","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.expneurol.2024.115040_bb0355","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2024.114704","article-title":"Positive relation between dopamine neuron degeneration and metabolic connectivity disruption in the MPTP plus probenecid mouse model of Parkinson\u2019s disease","volume":"374","author":"Tassan Mazzocco","year":"2024","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.expneurol.2024.115040_bb0360","doi-asserted-by":"crossref","first-page":"S353","DOI":"10.3233\/JPD-230385","article-title":"Imaging biomarkers in prodromal and earliest phases of Parkinson\u2019s disease","volume":"14","author":"Theis","year":"2024","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.expneurol.2024.115040_bb0365","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1046\/j.1471-4159.2000.740721.x","article-title":"Alpha-synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the parkinsonian toxin MPTP","volume":"74","author":"Vila","year":"2000","journal-title":"J. Neurochem."},{"key":"10.1016\/j.expneurol.2024.115040_bb0370","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/syn.20089","article-title":"Selective alterations of gene expression in mice induced by MPTP","volume":"55","author":"Xu","year":"2005","journal-title":"Synapse"},{"key":"10.1016\/j.expneurol.2024.115040_bb0375","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s12035-020-02128-5","article-title":"Molecular regulatory mechanism and toxicology of neurodegenerative processes in MPTP\/probenecid-induced progressive Parkinson\u2019s disease mice model revealed by transcriptome","volume":"58","author":"Yang","year":"2021","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.expneurol.2024.115040_bb0380","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.neulet.2004.05.118","article-title":"Inhibition of tyrosine hydroxylase expression in alpha-synuclein-transfected dopaminergic neuronal cells","volume":"367","author":"Yu","year":"2004","journal-title":"Neurosci. Lett."}],"container-title":["Experimental Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014488624003662?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014488624003662?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T03:53:03Z","timestamp":1732938783000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014488624003662"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":76,"alternative-id":["S0014488624003662"],"URL":"https:\/\/doi.org\/10.1016\/j.expneurol.2024.115040","relation":{},"ISSN":["0014-4886"],"issn-type":[{"value":"0014-4886","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Early \u03b1-synuclein\/synapsin III co-accumulation, nigrostriatal dopaminergic synaptopathy and denervation in the MPTPp mouse model of Parkinson's Disease","name":"articletitle","label":"Article Title"},{"value":"Experimental Neurology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.expneurol.2024.115040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115040"}}